The Combination of CD147 and MMP-9 Serum Levels Is Identified as Novel Chemotherapy Response Markers of Advanced Non-Small-Cell Lung Cancer

Table 1

The correlation between serum CD147 and MMP-9 levels before chemotherapy and clinical characteristics in patients with NSCLC.

Characteristics	CD147 (pg/mL)		MMP-9^[12] (μg/mL)
Gender		0.959		0.121
Male	566.30 (55.88-643.03)		2.80 (1.08-6.96)
Female	568.33 (461.50-643.03)		2.29 (0.80-3.59)
Age		0.676		0.536
≤60	572.62 (55.88-910.80)		2.61 (0.80-5.49)
>60	551.34 (281.00-822.25)		2.79 (1.08-6.96)
Smoking status		0.637		0.965
Never	568.34 (176.00-643.03)		2.87 (1.34-4.84)
Smoker	565.03 (55.88-910.80)		2.74 (0.80-6.96)
Baseline ECOG PS		0.543		0.301
0-1	568.58 (55.88-910.80)		2.74 (0.80-6.96)
2	554.35 (510.80-781.11)		3.66 (1.49-6.00)
Histological subtype		0.481		0.499
Adenocarcinomas	561.25 (55.88-910.80)		2.81 (1.08-6.00)
Squamous cell carcinomas	571.36 (281.00-822.25)		2.63 (0.80-6.96)
T status		0.217		0.928
T1	607.60 (196.05-613.79)		2.17 (1.82-4.02)
T2	554.35 (434.00-692.02)		2.72 (0.80-3.79)
T3	498.33 (55.88-650.73)		2.51 (1.49-6.96)
T4	597.16 (176.00-910.80)		2.82 (1.08-6.34)
N status		0.423		0.800
N0	591.47 (340.00-805.80)		2.55 (1.82-4.20)
N1	314.89 (55.88-573.90)		2.82 (2.49-3.16)
N2	545.35 (176.00-678.60)		2.83 (1.49-4.84)
N3	562.82 (281.00-910.80)		2.71 (0.80-6.96)
M status		0.287		0.497
M0	551.34 (55.88-650.73)		2.72 (0.80-6.96)
M1	569.84 (176.00-910.80)		2.78 (1.08-6.34)
TNM stage		0.287		0.497
III	551.34 (55.88-650.73)		2.72 (0.80-6.96)
IV	569.84 (176.00-910.80)		2.78 (1.08-6.34)

NCSCL: non-small-cell lung cancer; ECOG: Eastern Cooperative Oncology Group; PS: performance status.